Compare
Actinium Pharmaceuticals, Inc. vs Connect Biopharma Holdings Ltd vs Serina Therapeutics, Inc. vs Avalo Therapeutics, Inc.
| Latest fiscal year | Actinium Pharmaceuticals, Inc. ATNM | Connect Biopharma Holdings Ltd CNTB | Serina Therapeutics, Inc. SER | Avalo Therapeutics, Inc. AVTX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $90.0K | $64.0K | $130.0K | $59.0K |
| Revenue growth (YoY) | n/a | -99.8% | +132.1% | -86.6% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/m | n/m | n/m | n/m |
| Net margin | n/m | n/m | n/m | n/m |
| Net income | -$33.89M | -$55.48M | -$19.18M | -$78.26M |
| EPS (Diluted) | -$1.09 | -$1.00 | -$1.91 | -$5.84 |
| Operating cash flow | -$24.58M | -$51.21M | -$17.95M | -$51.46M |
| Free cash flow | -$24.68M | -$51.64M | -$18.01M | n/a |
| Cash & equivalents | $48.00M | $38.34M | $3.06M | $15.86M |
| Total assets | $51.77M | $56.08M | $6.95M | $116.46M |
| Total liabilities | $43.94M | $14.10M | $6.99M | $33.41M |
| Shareholders' equity | $7.83M | $41.98M | -$37.0K | $83.05M |
| Return on year-end equity | -432.6% | -132.2% | n/a | -94.2% |
| Shares outstanding | 31.20M | 56.44M | 10.77M | 18.51M |
Revenue, most recent five fiscal years
| Fiscal year | Actinium Pharmaceuticals, Inc. | Connect Biopharma Holdings Ltd | Serina Therapeutics, Inc. | Avalo Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $90.0K Ended 2025-12-31 | $64.0K Ended 2025-12-31 | $130.0K Ended 2025-12-31 | $59.0K Ended 2025-12-31 |
| 1 year earlier | n/a | $26.03M Ended 2024-12-31 | $56.0K Ended 2024-12-31 | $441.0K Ended 2024-12-31 |
| 2 years earlier | $81.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $3.15M Ended 2023-12-31 | $1.92M Ended 2023-12-31 |
| 3 years earlier | $1.03M Ended 2022-12-31 | n/a | $34.0K Ended 2022-12-31 | $18.05M Ended 2022-12-31 |
| 4 years earlier | $1.14M Ended 2021-12-31 | n/a | $144.0K Ended 2021-12-31 | $5.40M Ended 2021-12-31 |